HD-OPM Archive
Topics › Heart rhythm & heart failure

Heart failure in 2026: SGLT2 inhibitors foundational, HFpEF now treatable, early GDMT

Louis Nervegna · Mar 29, 2026 · ♥ 4 reactions · 0 comments · original Facebook post
Heart rhythm & heart failureGLP-1 drugs (semaglutide, tirzepatide)
AI summary & key facts

A Cardiophilia summary of the latest heart failure evidence update lists several shifts: SGLT2 inhibitors are foundational across the ejection fraction spectrum, HFpEF now has options (finerenone, GLP-1 and incretin therapies), guideline therapy starts in-hospital, decongestion becomes guided by urine sodium, and devices are integrated into care.

#heartfailureHD

🫀Heart failure in 2026: we are no longer treating symptoms. We are redesigning the disease.

The latest evidence update reminds us of something profound:

Heart failure is no longer a single entity.
It is a spectrum, and now, finally, we are treating it as one.

Several paradigm shifts stand out.

  1. SGLT2 inhibitors are no longer “add-on” therapy.

They are foundational across the entire EF spectrum.

From HFrEF to HFpEF, the data are now consistent.
Not just symptom improvement, but hard outcomes.

This may be the most important unifying therapy in modern HF.

  1. HFpEF is no longer a therapeutic desert.

For the first time, we have real disease-modifying options:

Finerenone → outcome reduction across EF ranges

GLP-1 / dual incretin therapies → targeting the obesity phenotype

Structural and metabolic mechanisms are finally being addressed

We are moving from “HFpEF frustration” → HFpEF phenotyping.

  1. Acute heart failure is no longer about stabilization.

It is about early transformation.

The new paradigm:

Start GDMT in-hospital

Optimize rapidly

Treat beyond congestion

Decongestion is still important, but it is no longer the goal.
Disease modification starts on day 1.

  1. Decongestion is becoming precision medicine

Urine sodium-guided therapy

Early escalation of loop diuretics

Sequential nephron blockade

Not just “give furosemide”, but measure, adjust, and target response.

  1. Devices are no longer rescue therapy, they are integrated care

TEER expanding from mitral → tricuspid

Pulmonary artery pressure monitoring reducing hospitalizations

Remote hemodynamics shaping outpatient management

The boundary between ICU, ward, and home is dissolving.

  1. The biggest problem is no longer evidence.

It is implementation.

We already have:

Quadruple therapy

Proven outcome benefits

Yet many patients never reach target doses.

The gap is no longer science.
It is execution.

🤓Final message

Heart failure care has entered a new era:

Mechanism-based therapy

Early aggressive optimization

Phenotype-driven treatment

And perhaps most importantly:
We are no longer chasing symptoms.
We are altering the trajectory of the disease.

No photo description available.
#sglt2#paradigm#precisionmedicine#obesity#sodium
← newer: Hormone therapy has no proven dementia benefit and may add rolder: PREDIMED: free nuts roughly halved stroke risk, and walnuts →